In patients with ST-segment elevation myocardial infarction, those given elamipretide had a lower median serum HtrA2 than those without it (496.5 vs 1805.5 pg/mL).
In plain wordsIn heart attack patients, blood HtrA2, a possible marker of heart cell damage, was lower with elamipretide than without it.
- Peptide
- Elamipretide (SS-31)
- Outcome
- DecreaseSerum HtrA2 level after myocardial infarction
- Study
n = 19
- Comparator
- STEMI patients without elamipretide
- Outcome group
- Myocardial injury · Cardiovascular
- Studied dose
- Dose not stated
Measurements
- HtrA2 median serum level
- 496.5 pg/mL
- elamipretide
- HtrA2 median serum level
- 1805.5 pg/mL
- STEMI patients without elamipretide
Source sentences
Elamipretide significantly reduced the HtrA2 median serum level after myocardial infarction 1805.5 (981.3-2220.1) pg/mL vs. 496.5 (379.4-703.8) pg/mL (P⩽0.05).
2 context sentences(design, population, supporting numbers)
After informed consent, peripheral blood was obtained from patients (n=19) with first-time acute anterior STEMI after percutaneous coronary intervention.
Within this group, 10 of the patients received the mitochondria-targeting peptide elamipretide (phase 2a clinical study EMBRACE (NCT01572909)).